BACKGROUND: Osteoclastic activity is mainly assessed by measuring urinary markers. To correct for differences in renal clearance, the levels of urinary markers are usually corrected by the urine creatinine concentration. Therefore, alternative serum markers to evaluate osteoclastic activity are required. We developed a novel system for the determination of serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity to evaluate osteoclastic activity. METHODS: Two unique monoclonal antibodies were generated and the specificity was tested using a surface enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS). A novel fragments absorbed immunocapture enzymatic assay (FAICEA) method was developed using 2 monoclonal antibodies. RESULTS: FAICEA gave a sensitivity 0.1 U/l, linearity of 0.1-28 U/l, recovery 92-103%, inter-assay CV 2.95% and intra-assay CV 2.15%. Unlike other TRACP5b assay systems, FAICEA avoided interference from TRACP 5a. CONCLUSIONS: According to the FAICEA, postmenopausal women had higher TRACP5b concentrations than younger women. The results show that TRACP5b is a novel bone resorption marker in serum.
BACKGROUND:Osteoclastic activity is mainly assessed by measuring urinary markers. To correct for differences in renal clearance, the levels of urinary markers are usually corrected by the urine creatinine concentration. Therefore, alternative serum markers to evaluate osteoclastic activity are required. We developed a novel system for the determination of serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity to evaluate osteoclastic activity. METHODS: Two unique monoclonal antibodies were generated and the specificity was tested using a surface enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS). A novel fragments absorbed immunocapture enzymatic assay (FAICEA) method was developed using 2 monoclonal antibodies. RESULTS: FAICEA gave a sensitivity 0.1 U/l, linearity of 0.1-28 U/l, recovery 92-103%, inter-assay CV 2.95% and intra-assay CV 2.15%. Unlike other TRACP5b assay systems, FAICEA avoided interference from TRACP 5a. CONCLUSIONS: According to the FAICEA, postmenopausal women had higher TRACP5b concentrations than younger women. The results show that TRACP5b is a novel bone resorption marker in serum.
Authors: M Kurajoh; M Inaba; S Okuno; H Nagayama; S Yamada; Y Imanishi; E Ishimura; S Shoji; T Yamakawa; Y Nishizawa Journal: Osteoporos Int Date: 2010-05-07 Impact factor: 4.507
Authors: Y Nagata; M Inaba; Y Imanishi; H Okazaki; S Yamada; K Mori; S Shoji; H Koyama; S Okuno Journal: Osteoporos Int Date: 2014-11-18 Impact factor: 4.507
Authors: S Okuno; E Ishimura; N Tsuboniwa; K Norimine; K Yamakawa; T Yamakawa; S Shoji; K Mori; Y Nishizawa; M Inaba Journal: Osteoporos Int Date: 2012-05-12 Impact factor: 4.507